StemCell Therapy

Dublin, March 05, 2020 (GLOBE NEWSWIRE) -- The "Worldwide Wound Care Market Summary" report has been added to ResearchAndMarkets.com's offering.

Wound care is very much a challenge for both patients and healthcare providers.

Worldwide Wound Care Market Summary identifies a market opportunity for major sectors of this important market. A particular focus is given to biotechnology used in wound care, including advanced biodressings and negative pressure wound systems.

Advancements in biotechnology, biomaterials, and tissue engineering are expected to drive growth in the market during the report's forecast period. Growth is also being driven by the introduction of portable, single-use products in negative pressure wound therapy.

The report focuses on wound care advancements, providing a table of newly approved wound care products for 2019. The aging of the population and continued advances in biotechnology drive the wound care industry. It is the goal of new and existing product manufacturers to offer products designed to improve healing rates and prevent wound formation.

Market data in the report include:

World Market

Total Market by Segment

Market Segments by Application

Market by Application

The report also contains current market size for the total wound care products market for the following countries and regions:

Worldwide Wound Care Market Summary provides an outline of the competitive market, including the following data points:

Industry participants have attempted to diversify their offerings by acquiring smaller companies with new and innovative technology. This move has created more competition among large wound care companies.

Key Topics Covered

Chapter 1: Executive Summary

Chapter 2: Total Worldwide Wound Care Market Size, Forecast, and Competitive Analysis

Chapter 3: Wound Care Advancements

Chapter 4: Top Five Company Profiles(Company Overview, Performance Review)

A-Z List of Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/eyoxce

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Visit link:
Worldwide Wound Care Market Summary 2017-2024 - Focus on Biotechnology: Advanced Biodressings, Negative Pressure Wound Systems, and More -...

The decision to buy or sell a stock is dependent not only on the company fundamentals but also on its trading price. Many strong businesses enter the avoid or sell zone, simply because of exaggerated prices and seemingly little to no upside potential. One such stock that a value investor needs to shy from is Vir Biotechnology (VIR).

Today, we will see why fundamentals fail to justify Vir Biotechnology's valuation levels.

Vir Biotechnology is a clinical-stage immunology company focused on developing novel treatments targeting infectious diseases. The company's four therapeutic platforms, antibody platform, T Cell platform, Innate immunity platform, and siRNA platform, are working on enhancing the immune response to pathogens. The company's lead asset, VIR-2218, is currently being evaluated in Phase 2 in HBV (hepatitis B) indication. Besides, the company also has multiple early-stage investigational drug candidates being evaluated in tuberculosis, influenza, and HIV indications.

Recently, though, the stock has jumped over 100% on news of its involvement in researching antibodies that can work against the novel coronavirus or COVID-19 virus strain.

On February 12, Vir Biotechnology announced that it has identified two monoclonal antibodies that bind to the SARS-CoV-2 virus which causes the COVID-19 disease. These antibodies are targeting the SARS-CoV-2 spike protein in the region that the virus uses to enter cells through the cellular receptor ACE2. On February 25, the company announced a manufacturing collaboration with WuXi Biologics to advance and produce human monoclonal antibodies for the potential treatment of COVID-19.

Although these are promising developments especially in a world fighting a pandemic, the fact remains that the company is not even close to commencing first-in-human trials for the investigational COVID-19 therapeutic. The company has isolated antibodies from patients who survived SARS and is studying it for COVID-19 in the preclinical stage. The company may require around 10 months, provided everything goes without a glitch, to get the first human dosed with this therapy.

Gilead Sciences (GILD) seems to be much ahead in the quest of COVID-19 therapy. On February 26, the company announced the initiation of two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19. In these randomized, open-label, multicenter studies, the company plans to enroll 1,000 patients at medical centers primarily across Asian countries, as well as other countries globally with high numbers of diagnosed cases, beginning in March to evaluate two dosing durations of remdesivir, administered intravenously. FDA has already reviewed and accepted the company's IND (investigational new drug) filing for remdesivir for the treatment of COVID-19. This follows the article published in The NEJM (New England Journal of Medicine) which highlighted clinical benefit witnessed by a COVID-19 patient in the U.S. on the administration of remdesivir.

Remdesivir is already being studied in two clinical trials, in China's Hubei province led by the China-Japan Friendship Hospital as well as the recently initiated clinical trial in the United States led by the National Institute of Allergy and Infectious Diseases.

Then, there is Regeneron (REGN), also working on an antibody approach to finding a cure for COVID-19. The company's technology platform demonstrated robust outcomes in the Ebola outbreak of 2015.

There is also much activity in the vaccine space for COVID-19. We also have Moderna Therapeutics (MRNA) working with the NIH (National Institutes of Health) to evaluate mRNA-1273 as a vaccine candidate for COVID-19 in the Phase 1 trial. The company will be studying the vaccine candidate in the healthy-volunteer study expected to begin in April. If proven safe, Moderna and NIH plan to enroll hundreds of more patients to determine whether the vaccine protects against infection. We also see other companies such as Sanofi (SNY), Inovio Pharmaceuticals (INO), CureVac, and GlaxoSmithKline (NYSE:GSK), analyzing various vaccine candidates in the preclinical stage.

Vir Biotechnology is definitely not a forerunner in this race for COVID-19 treatment. Hence, the investor exuberance and the more than 100% jump in share prices since February 24 does not seem justified by company fundamentals.

Vir Biotechnology and Alnylam Pharmaceuticals (ALNY) are working on investigational subcutaneously administered HBV-targeting siRNA (Small interfering RNA), VIR-2218, in Phase 1/2 clinical trial. This drug is designed to inhibit the production of all HBV proteins including HBsAg (HBV surface antigen). HBsAg is developed by the HBV virus to inhibit T-cell activity against the infection.

In January 2020, Vir Biotechnology announced new pipeline data from the ongoing Phase 2 trial of VIR-2218. The data demonstrated substantial reductions in HBsAg and also high tolerability of the therapy. All HBeAg negative and positive patients who received two doses of 200 mg of VIR-2218 reported at least a 1.0 log10 decline in HBsAg as well as a mean decline of 1.5 log10 in HBsAg at day 85.

Further, none of the patients demonstrated ALT (alanine amino transaminase) greater than or equal to three times the upper limit of normal, validating the manageable tolerability profile of the therapy.

Vir Biotechnology expects 16-week data across all cohorts in the first half of 2020. The company also plans to commence two new trials with VIR-2218 by late 2020. These include a Phase 2 trial in China in collaboration with Brii Biosciences, and another Phase 2 combination trial of VIR-2218 and pegylated interferon-alpha (PEG-IFN-). The company is also working on advancing CTA (clinical trial application) for the investigational HBV vaccine, VIR-3434, in the first half of 2020.

Although there are impending milestones and catalysts for Vir Biotechnology in 2020, none of them justify the company's current valuation multiples. Currently, Vir Biotechnology is trading at a price-to-sales multiple of 626.43x and price-to-cash flow multiple of 19.95x.

Other hepatitis B players such as Ionis Pharmaceuticals (IONS), GlaxoSmithKline, Arrowhead Pharmaceuticals (ARWR), and Arbutus Biopharma are trading at much lower price-to-sales multiples of 6.88x, 2.55x, 22.46x, and 30.80x, respectively.

Besides the valuations, there are many other risks associated with this company. Vir Biotechnology is a clinical-stage company and can continue to report losses for many more years. Infectious disease players have historically got the short end of the stick in terms of biopharmaceutical funding. Unlike chronic lifestyle conditions, there may come a stage when a majority of infectious disease patients are cured. We have seen this for the Gilead Sciences Hepatitis C franchise. There remains a high possibility that after the initial bolus of patients, hepatitis B players may also face a rapid decline in the addressable market and extraordinary profits.

The company is also in the early stage of clinical development and faces significant R&D failure risk. It does not have a history of advancing molecules in the late-stage of clinical development or of securing regulatory approvals. The company also does not have experience of successfully commercializing products. This exposes the company to a significant degree of market uncertainty.

One upside for the company, however, is its stable cash balance of around $320 million at the end of September 2019. Assuming that the company's cash burn rate is similar to the cash spent on operational activities of around $120 million in 12 months ending September 2019, the company may not need dilutive financing at least till the end of 2021. However, the company may still choose to go for equity dilution to take advantage of its stratospheric valuations.

According to finviz, the 12-month consensus target price for the stock is $26.33. On February 27, Baird analyst Madhu Kumar downgraded Vir Biotechnology to Underperform from Neutral and reiterated the target price of $17. On February 4, JPMorgan analyst Anupam Rama downgraded Vir Biotechnology to Neutral from Overweight but raised the price target from $25 to $26.

In November 2019, Goldman Sachs analyst Paul Choi initiated coverage with a Buy rating and $37 price target. Barclays analyst Gena Wang initiated coverage with an Overweight rating and $25 price target.

Here again, we see that the modest fiscal 2020 revenue and EPS estimates do not support Vir's high valuations.

In this backdrop, I believe that a target price range of $25 to $28 is a fair estimate of the true growth potential of Vir Biotechnology in 2020. This is definitely a promising biotechnology company, but investors should not pick this company at unsustainable valuations. Instead, it is advisable even for aggressive investors to wait for a better entry point to pick this stock in 2020.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Read more:
Vir Biotechnology: Avoid This Overvalued Stock In March 2020 - Seeking Alpha

The global life sciences tools market has been growing with advancements in the field of biological research and testing. It is evident that the global life sciences sector has been transforming into a pool for investment and lucrative growth. The changing financial trends pertaining to this sector have given a boost to the growth of the global life sciences tools market. The presence of multiple biological research institutes has given a thrust to the growth of the global life sciences tools market. Moreover, the focus given on improved biotechnologies by medical professionals has also generated stellar demand within the global market.

This blog by Transparency Market Research (TMR) on the global life sciences tools market is a deft explanation of the forces that have aided market growth.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2358

The growing incidence of genetic disorders has played a major role in the growth of the global life sciences tools market. The domain of molecular biology has emerged as a haven of opportunities due to the advent of improved research facilities. The use of life sciences tools such as instruments, reagents, and consumables in the field of biomedicine has given a strong impetus to the growth of the global market.

On the basis of geography, the global life sciences tools market can be segmented into North America, the Middle East and Africa, Europe, Latin America, and Europe. The life sciences tools market in North America is expanding with advancements in the domain of biochemical research.

Request For Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=2358

Geographically, the global life sciences tools market is segmented into Europe, North America, Asia Pacific, and Rest of the World. Of these, North America has led a leading position and is projected to maintain its stance in the coming years. The North America life sciences tools markets position will be attributable to the increasing investments in research and development activities. The strong presence of pharmaceutical companies in the region are also expected to make a significant contribution to the markets rising revenue.

The Asia Pacific life sciences tools market is also show steady progress over the next few years. The emergence of the healthcare sector in the region and the increasing expenditure on treatment of various conditions are expected to propel the market in this region. The improving economic conditions of the developing countries in Asia Pacific are also expected to bode well with the regional market.

Pre Book Life Science Tools Market Research - https://www.transparencymarketresearch.com/checkout.php?rep_id=2358&ltype=S

Key Players Mentioned in the Report are:

The leading players operating in the global life sciences tools market are F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., EMD Millipore (Merck KGaA), Sigma-Aldrich Corporation, and Life Technologies (Thermo Fisher Scientific Corporation).

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Original post:
Global Life Science Tools Market to Expand with Advancements in the Field of Biotechnology - BioSpace

The House of Representatives passed a bill for allotment of funds in an emergency pool earlier this week, which is to be used to counter the damaging effects of the coronavirus outbreak is expected to have on the domestic economy.

Let us analyze which stocks are expected to benefit from this emergency stash.

House Allocates $8 Billion to Emergency Funds

On Mar 4, the House passeda legislation that allocates more than $8 billion to emergency funds to battle against the spread of coronavirus. The bill won by a voting ratio of 415-2. Republican lawmakers Ken Buck of Colorado and Andy Biggs of Arizona were the only members who voted unfavorably.

The emergency funds aim to provide more than $3 billion for vaccine research and $2.2 billion for efforts in prevention and preparedness. Medical tests and vaccine research to combat the pandemic are urgent tasks right now, which many biotechnology firms in the country are working on actively.

Companies, such as Moderna, Inc. MRNA, Inovio Pharmaceuticals, Inc. INO and Vir Biotechnology, Inc. VIR are currently in the process of developing the much-needed vaccines.

The congressional spending proposal is considerably higher than the $2.5 billion that the White House had proposed in late February. The bill also authorizes about $500 million to allow Medicare providers to offer telehealth services, which would benefit elderly patients to receive care in the comforts of their homes.

The bill is now headed to the Senate for approval. Should it be passed effectively, it will then make its way to President Donald Trumps desk, who is expected to give a green signal. Trump had earlier indicated at a news conference that he would spend whatever is appropriate to fight the COVID-19 outbreak.

After all, death toll in the United States climbed to 11 and minimum 138 are infected. Of the 11, 10 deaths were confirmed from Washington while one was registered in California. Globally, the pandemic claimed more than 3,100 lives.

Story continues

3 Stocks in Focus

We have, therefore, handpicked three vital stocks that are actively developing vaccines to address the novel coronavirus. One may take a closer look at these.

Modernais a clinical stage biotechnology company. Last week, the company saidthat its first batch of vaccine against the COVID-19 disease, called mRNA-1273, was ready for the government to test on humans.

The Zacks Consensus Estimate for Modernas current-year earnings has moved 5% north in the past 60 days. Shares of this company, which belongs to the Zacks Medical - Biomedical and Geneticsindustry, have risen 40.5% against the industrys decline of 2.6% on a year-to-date basis. (Read more)

Moderna carries a Zacks Rank #2 (Buy). You can seethe complete list of todays Zacks #1 Rank (Strong Buy) stocks here.

Inovio Pharmaceuticalson Mar 4 announcedan accelerated timeline to develop its DNA vaccine INO-4800 to battle COVID-19. Inovio's President & CEO Dr. J. Joseph Kim mentioned this accelerated timeline at the U.S. Coronavirus Task Force meeting at the White House on Mar 2.

Inovio Pharmaceuticals carries a Zacks Rank #3. Shares of this company, which belongs to the Zacks Medical - Biomedical and Geneticsindustry, have risen 143.2% against the industrys decline of 2.6% on a year-to-date basis.

Vir Biotechnologyis a clinical-stage immunology company. The firm, along with Alnylam Pharmaceuticals, Inc. ALNY, announcedon Mar 4 that the two companies would expand their continuing collaboration to make an attempt to develop RNA interference treatments for SARS-CoV-2.

Vir Biotechnology carries a Zacks Rank #3. Shares of this company, which belongs to the Zacks Medical - Biomedical and Geneticsindustry, have risen 257% against the industrys decline of 2.7% on a year-to-date basis.

Free: Zacks Single Best Stock Set to Double

Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.

This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the companys drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.

See 5 Stocks Set to Double>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportModerna, Inc. (MRNA) : Free Stock Analysis ReportAlnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis ReportInovio Pharmaceuticals, Inc. (INO) : Free Stock Analysis ReportVir Biotechnology, Inc. (VIR) : Free Stock Analysis ReportTo read this article on Zacks.com click here.

Read this article:
House Okays $8 Billion Funds to Combat COVID-19: 3 Winners - Yahoo Finance

Provention Bio Inc (PRVB) is near the top in its industry group according to InvestorsObserver. PRVB gets an overall rating of 82. That means it scores higher than 82 percent of stocks. Provention Bio Inc gets a 96 rank in the Biotechnology industry. Biotechnology is number 21 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Provention Bio Inc (PRVB) stock is trading at $11.46 as of 2:34 PM on Tuesday, Mar 3, a drop of -$0.78, or -6.37% from the previous closing price of $12.24. The stock has traded between $11.31 and $12.71 so far today. Volume today is less active than usual. So far 305,664 shares have traded compared to average volume of 536,536 shares.

To see InvestorsObserver's Sentiment Score for Provention Bio Inc click here.

Originally posted here:
Industry Analysis: Should You Buy Provention Bio Inc (PRVB) in Biotechnology? - InvestorsObserver

Researchers from German Fraunhofer IGBI have used next-generation sequencing (NGS) to diagnosis sepsis from tiny amounts of microbial DNA in the blood.

In theJournal of Molecular Diagnostics, a research team led by Kai Sohn from Fraunhofer IGB (Stuttgart, Germany) describes the new real-time NGS-based technique that allows an accurate diagnosis of sepsis-causing agents within a few hours of drawing blood. Current diagnostic tests are culture- or PCR-based, which are neither fast nor specific enough to provide timely, critically important information.

"With up to 50 million incident sepsis cases and 11 million sepsis-related deaths per year, sepsis represents a major cause of dealth," explained co-lead-investigator Thorsten Brenner, MD, vice head of the Department of Anesthesiology, Heidelberg University Hospital, Heidelberg, Germany. "Reliable and early identification of the pathogen enables rapid and the most appropriate antibiotic intervention, thereby increasing the chance of better outcomes and patient survival. Currently, standard-of-care diagnostics still rely on microbiological culturing of the respective pathogens, which rarely provide timely positive results."

The investigators described a system that utilized NGS of microbial cell-free DNA to detect blood pathogens within 28 hours. However, their ultimate goal was to develop an even faster test to expedite treatment. To overcome this limitation the investigators established a diagnostic workflow based on 3rd generation nanopore sequencing of microbial DNA. Normally, nanopore sequencing is used to analyze long fragments in sufficient amounts. However, microbial cell-free DNA occurs in small fragments and low quantities in plasma. Nanopore sequencing offers the possibility of real-time analyses during sequencing, which dramatically reduces the time needed to obtain results. "We also had to create validated, specifically adapted bioinformatic procedures to reliably identify pathogens," noted Sohn.

This new technique relies on the use of the handheld nanopore sequencer MinION developed by Oxford Nanopore Technologies. According to the company, the handheld sequencer can read out ultra-long reads, and immediately processes reads in real time.

In their pilot study, the investigators analysed plasma from four septic patients and three healthy controls who were hospitalized in the intensive care unit (ICU). Each sample's DNA underwent sequencing using both technologies: the standard NGS (from world market NGS leader Illumina, which finished a MinION partnership) and the nanopore NGS technology. With nanopore sequencing, all septic patient samples were found to be positive for relevant pathogens, whether bacterial, viral, or fungal.

After additional refinements, the new technique was able to achieve a 3.5-fold increase in sequencing throughput, allowing pathogen identification within minutes after sequencing began. In fact, the highest quality results were generated within 2 or 3 hours of the beginning of sequencing. In contrast, with Illumina the final results are available only after the sequencing is finished. "This new system might facilitate same-shift adaption of antibiotic intervention at the ICU, which might, in turn, improve patient outcomes significantly,"suggested Sohn. In an additional retrospective analysis of 239 samples taken from sepsis patients, however, the accuracy of nanopore sequencing was lower than with Illumina (85% vs. 99%).

"Time consuming, error- and contamination-prone blood cultures are still considered as the standard of care for sepsis diagnostics, frequently leading to an inappropriate and delayed targeted therapy," said Prof. Dr. Brenner. "The nanopore sequencing platform sequences in real time and has the potential to reduce time to diagnosis to only a few hours."

As with every DNA-based method, however, researchers are only able to get information about antibiotic resistance genes, that is which antibiotics won't be effective. To know which antibiotics actually are effective they'd need confirmatory culture-based methods.

Read this article:
German and UK researchers cut time to sepsis diagnosis - European Biotechnology

At the end of the latest market close, Vir Biotechnology, Inc. (VIR) was valued at $40.97. In that particular session, Stock kicked-off at the price of $42 while reaching the peak value of $47.47 and lowest value recorded on the day was $41.71. The stock current value is $44.90.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Vir Biotechnology, Inc. shares are logging -40.13% during the 52-week period from high price, and 285.39% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $11.65 and $75.00.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 1.07 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Vir Biotechnology, Inc. (VIR) recorded performance in the market was 257.06%, having the revenues showcasing 240.15% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 6.38B, as it employees total of 217 workers.

Raw Stochastic average of Vir Biotechnology, Inc. in the period of last 50 days is set at 52.22%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 48.91%. In the last 20 days, the companys Stochastic %K was 46.74% and its Stochastic %D was recorded 50.97%.

If we look into the earlier routines of Vir Biotechnology, Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 257.06%. The shares increased approximately by 1.54% in the 7-day charts and went down by 28.38% in the period of the last 30 days. Common stock shares were driven by 240.15% during last recorded quarter.

Read more from the original source:
Vir Biotechnology, Inc. (VIR) distance from 20-day Simple moving Average is 76.19% : What to Expect? - The InvestChronicle

The Global Single-use Bioprocessing Material Market by Product Type (Plastic, Silicone and Other) and by End-Users/Application (Life Science RD and Academic Research Institutes, Biopharmaceutical Manufacturers, Contract Research Organization and Other) Global Market Share, Forecast Data, In-Depth Analysis, and Detailed Overview, and Forecast, 2015 2027 report has been added to ProficientMarket.coms offering.

In the recent years single-use technologies have evolved to become a mainstream approach for achieving productivity. Generally, Single-use Bioprocessing Material Market consists of disposable products that assist in manufacturing biopharmaceutical products. Moreover, these products have also proved to be beneficial for the small scale pharmaceutical manufacturers. Therefore, most of the biopharmaceutical companies utilize single-use bioprocessing technology for manufacturing vaccines, monoclonal antibodies, and other pharmaceutical components on a commercial scale.

In terms of revenue, Global Single-use Bioprocessing Material Market in 2018 stood at USD XX million and is expected to reach USD XX million by 2026 growing at a CAGR of 17.95% from 2019 to 2026.

Read the full Global Single-use Bioprocessing Material Market Report: https://proficientmarket.com/report/1083/global-single-use-bioprocessing-material-market

Some of the global major players operating in the Single-use Bioprocessing Material market include: Applikon Biotechnology B.V., Cesco Bioengineering Co. Ltd., GE Healthcare (General Electric Company), Sartorius Stedim Biotech S.A, Thermo Fisher Scientific, 3M Company, Eppendorf AG, Finesse Solutions, Inc., Others.

Drivers for the Global Single-use Bioprocessing Material Market: Growth of this market is propelled by rise in adoption of single use technologies across pharmaceutical manufacturing facilities, low risk of product cross contamination, cost-effectiveness, less floor space requirement, high energy efficiency, low water usage, container or closure systems, mixing systems, fermentation systems, and cell culture systems and faster to implement are the key drivers for the growth of the global single use bioprocessing market.

Opportunities for the Global Single-use Bioprocessing Material Market: This market has great opportunities in construction of media bags along with the films used in the bioprocess containers. Additionally, emerging markets such as Brazil, China, and India provide new growth opportunities to players in the single-use bioprocessing market.

Restrains for the Global Single-use Bioprocessing Material Market: On the other hand, extractability and leachability issues regarding disposable components like plastic bags, and environmental and economic concerns are the major factors that are restraining the growth of the single use bioprocessing market.

Get Free Sample PDF (including full TOC, Tables and Figures) of Single-use Bioprocessing Material Market @ https://proficientmarket.com/sample/1083

Region Wise, Global Single-use Bioprocessing Material Market Analysis: Can be segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Among all, Asia Pacific leads the Global Single-use Bioprocessing Material Market share due to improving R&D infrastructure, rising focus of market players, and increasing government initiatives as well as significant growth of pharmaceutical and the biotechnology industries across the countries of Asia-Pacific region which is followed by the North America and Europe.

Global Single-use Bioprocessing Material Market: Product analysisPlasticSiliconeOther

On the basis of type, Plastic accounted for largest share of total revenue generated. Because of their large use in manufacturing of polyethylene.

Global Single-use Bioprocessing Material Market: Application analysisLife Science RD and Academic Research InstitutesBiopharmaceutical ManufacturersContract Research OrganizationOther

The demand of Global Single-use Bioprocessing Material Market is highest from Biopharmaceutical Manufacturers, due to high energy efficiency, low water usage, less floor space requirement and very low risk of product cross contamination.

Global Single-use Bioprocessing Material Market: Region analysisNorth America: U.S., Canada, MexicoEurope: U.K., France, Germany, Spain, Italy, Rest of EuropeAsia Pacific: China, Japan, South Korea, ASEAN, IndiaRest of Asia Pacific: Latin America, Brazil, Argentina, Colombia, Rest of L.A.Middle East and Africa: Turkey, GCC, UAE, South Africa, Rest of Middle East

The report can be customized as per client requirements. For further queries, you can contact us on [emailprotected] or +1-773-800-2974. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

Read the full press release and latest news of this reports, here: https://proficientmarket.com/press-release/1083/global-single-use-bioprocessing-material-market

About Us:

Proficient Market is the leading research company offering both tactical and strategic support to all our customers. Customer satisfaction is our goal and that is why, we have a team of skilled and experienced specialist with the ability to do data mining, information management, and revenue enhancement solutions to ensure that our clients make informed decisions when coming to investing in the market. Our happiness is when we help our clients grow their business, strengthen the brands and educate their members or consumers through the ever new fun research methods developed by our team.

Contact Us:

Proficient Market1st Floor, Harikrishna Building,Samarth Nagar, New Sanghvi,Pune- 411027 IndiaTel: +91-8149441100 (GMT Office Hours)USA: +17738002974Email: [emailprotected]Web: proficientmarket.com

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at [emailprotected].

WiredRelease

Visit WiredRelease's Website

See more here:
Global Single-use Bioprocessing Material Market Key Players Profiled Applikon Biotechnology BV, Cesco Bioengineering Co. Ltd., GE Healthcare ,...

The research study presented in this report offers complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the Global Canine Stem Cell Therapy Market. The research study has been prepared with the use of in-depth qualitative and quantitative analyses of the global Canine Stem Cell Therapy market. We have also provided absolute dollar opportunity and other types of market analysis on the global Canine Stem Cell Therapy market.

It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Canine Stem Cell Therapy market. All findings and data on the global Canine Stem Cell Therapy market provided in the report are calculated, gathered, and verified using advanced and reliable primary and secondary research sources. The regional analysis offered in the report will help you to identify key opportunities of the global Canine Stem Cell Therapy market available in different regions and countries.

Request Sample Report @https://www.mrrse.com/sample/16152?source=atm

The authors of the report have segmented the global Canine Stem Cell Therapy market as per product, application, and region. Segments of the global Canine Stem Cell Therapy market are analyzed on the basis of market share, production, consumption, revenue, CAGR, market size, and more factors. The analysts have profiled leading players of the global Canine Stem Cell Therapy market, keeping in view their recent developments, market share, sales, revenue, areas covered, product portfolios, and other aspects.

Market Taxonomy

The global canine stem cell therapy market has been segmented into:

Product Type:

Application:

End User:

Region:

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/16152?source=atm

Canine Stem Cell Therapy Market Size and Forecast

In terms of region, this research report covers almost all the major regions across the globe such as North America, Europe, South America, the Middle East, and Africa and the Asia Pacific. Europe and North America regions are anticipated to show an upward growth in the years to come. While Canine Stem Cell Therapy Market in Asia Pacific regions is likely to show remarkable growth during the forecasted period. Cutting edge technology and innovations are the most important traits of the North America region and thats the reason most of the time the US dominates the global markets. Canine Stem Cell Therapy Market in South, America region is also expected to grow in near future.

The Canine Stem Cell Therapy Market report highlights is as follows:

This Canine Stem Cell Therapy market report provides complete market overview which offers the competitive market scenario among major players of the industry, proper understanding of the growth opportunities, and advanced business strategies used by the market in the current and forecast period.

This Canine Stem Cell Therapy Market report will help a business or an individual to take appropriate business decision and sound actions to be taken after understanding the growth restraining factors, market risks, market situation, market estimation of the competitors.

The expected Canine Stem Cell Therapy Market growth and development status can be understood in a better way through this five-year forecast information presented in this report

This Canine Stem Cell Therapy Market research report aids as a broad guideline which provides in-depth insights and detailed analysis of several trade verticals.

Buy This Report @ https://www.mrrse.com/checkout/16152?source=atm

More here:
Canine Stem Cell Therapy Market: Future Scenarios and Business Opportunity Analysis 2027 - Jewish Life News

Credit: Pixabay.

As news of the novel coronavirus dubbed COVID-19 by the World Health Organization makes headlines as it spreads through China and the rest of the world, most attention has been directed towards prevention and quarantine. While properly washing your hands and avoiding crowds is a good idea if you live near an area that has reported cases, its important to also take steps to boost your immune system in case you actually come in contact with the virus so the body can effectively fight back.

The immune system is designed to fight off infection and disease. It has a number of ways to detect and destroy anything it recognizes as foreign to your body, including bacteria, viruses, fungi, parasites or unhealthy cells such as cancer cells.

Viruses need the cell machinery in order to produce their own proteins. They are intracellular parasites that can only replicate inside cells, which is one of the reasons theyre not considered to be alive. The most effective mechanisms of the innate response against viral infections are mediated by interferon and by the activation of natural killer (NK) cells.

The strength of the immune system varies from person to person and, whats more, from day to day because its ability to fight off infection fluctuates depending on many factors. Here are a couple of things you can do to keep your immune system in check during the COVID-19 outbreak.

With all the daily headlines sowing doom and gloom about the novel coronavirus, its easy to stress over it. Some are so panicked that theyve begun stockpiling basic goods and food. Its a good idea to be prepared for any major emergency and this includes a viral outbreak however bear in mind that stress hormones tax the immune system, making its response to viral infections less effective.

In short supply, the stress hormone cortisol can boost immunity by limiting inflammation. But, once it crosses a certain threshold, too much cortisol in the blood opens the door for more inflammation. Stress also negatively impacts the production of lymphocytes the white blood cells that are the bodys first line of defense against infection putting you at risk of viral disease.

During this particularly stressful period, try not to panic because youll only make matters worse. Remember, the effects of stress are cumulative, meaning even ordinary, day-to-day activities can eventually lead to more serious health issues.

We already know that, for the vast majority of people that are already healthy, this is really more of an inconvenience to a lot of them than something that can be fatal or life-threatening, said Dr. Caroline Sokol, an immunology researcher at Massachusetts General Hospital.

To relieve stress, take breaks when you feel burned out and try to practice some relaxation techniques such as mindfulness, meditation, or positive thinking.

Regular exercise promotes cardiovascular health, lowers blood pressure, helps control body weight, and offers protection against diseases. Exercise also improves blood circulation, allowing immune system cells to move through the body more freely and do their job more effectively.

Although scientists have yet to establish a direct link between exercise and immune system health, its reasonable to presume that moderate regular exercise can help prevent disease by promoting overall health.

However, intense exercise can cause inflammation in the body that may send the immune system into overdrive. So, try not to take things overboard especially during times of seasonal viral outbreaks.

The immune system is the bodys natural defense system, and like any army, its warriors need sustenance. Its rather well established that people who live in poverty and are malnourished are more vulnerable to infectious diseases.

Although there are have been few studies that tie the effects of nutrition directly to the development of infectious diseases, there is evidence pointing to the fact that various micronutrient deficiencies such as those of zinc, selenium, iron, copper, folic acid, and vitamins A, B6, C, and E can alter the immune response in animals.

Make sure you eat a balanced diet with fruits and vegetables in order to receive the right proportion of micronutrients.

Smoking tobacco has several effects on immune system health, such as:

Studies show that people who dont get quality sleep or enough sleep are more likely to get sick after being exposed to a virus.

When we sleep, the body releases proteins called cytokines while sleep deprivation decreases their production. Cytokines are paramount during times of infection or inflammation. Whats more, the production of antibodies and immune cells is reduced when you dont get enough sleep.

The optimal amount of sleep for most adults is between 7 and 8 hours. However, school-aged children and teenagers might need up to 10 hours of sleep.

A note on supplements. Although youll find bottles of pills and herbal supplements claiming to promote immunity or otherwise boost the immune system, there is no evidence that they actually bolster immunity.

Read the original here:
How to the boost immune system against coronavirus - ZME Science

Dr Nicolas Poirier reveals how immunotherapies can be designed to recalibrate the immune system for long-term maintenance of autoimmune remission.

Autoimmune conditions affect more than 23.5 million Americans and as many as one in four in the UK. According to recent statistics these conditions are on the rise and some, including Type I diabetes, are three times more common that a few decades ago. While treatments have been developed, there is no cure for autoimmune conditions most therapeutics focus on relieving inflammation and the pain associated with it.

Drug Target Reviews Hannah Balfour spoke with Dr Nicolas Poirier, the Chief Scientific Officer (CSO) of OSE Immunotherapeutics, to understand their novel approach to targeting and treating autoimmune diseases; using immunology to rebalance the immune system.

because their therapeutics target the immune system, rather than a localised specific tissue, the products are transferable between different autoimmune conditions

A lot of companies focus on inhibiting or killing immune cells, but what we have learned in the last five to 10 years is that not all immune cells are pathogenic. There are bad guys of course, but there are also good guys in the immune system, which help to fight or control autoimmune attacks, explained Dr Poirier. He clarified that for each immune cell, there is a corresponding regulatory subtype, such as the well-known T regulatory (Treg) cells. B cells also have a regulatory subtype and so do macrophages.

Dr Poiriers team target their products to specifically inhibit the pathogenic cells and activate the regulatory cells, manipulating the balance of the immune system to reduce autoimmunity. While this may have various short-term effects on disease symptoms, the overarching goal is to maintain remission and prevent flare-ups in the long term.

At present, the company has two therapeutics in trials, which, according to their CSO, have similar effects but utilise different biologic mechanisms of action.

Both are therapies using monoclonal antibody (mAb) fragments as their active pharmaceutical ingredient (API). Dr Poirier revealed the use of fragments was particularly important in establishing a safe level of toxicity.

OSE-104 is a mAb fragment therapy which selectively binds to the CD28 T-cell receptor to block activation of T cells that have the potential to be pathogenic. They also discovered that their fragment can promote Treg cell expansion.According to Dr Poirier, other companies have attempted to develop similar therapies using full mAbs and despite working well in a murine model, they turned out to be traumatically toxic in humans, because they activate the receptors and as a result the whole immune system. Instead, his team developed antibody fragments large enough to specifically bind target receptors, but that are unable to activate the receptors they bind to, blocking them instead.

Interleukin 7 (IL-7) is a haematopoietic growth factor secreted by stromal cells in the bone marrow and thymus. It is produced by keratinocytes, neurons and epithelial cells, but is not by normal T lymphocytes.

It is also thought that CD127 may be involved in transforming T cells into memory T lymphocytes.A second drug, OSE-127, with a similar mode of action, is expected to enter Phase II trials in 2020. These immunomodulatory mAb fragments target the CD127 receptors on the surface of T cells. CD127 receptors are alpha chains of IL-7 receptors (IL-1Rs) that bind IL-7 and are expressed on the surface of effector T cells. IL-7 regulates the migration of effector T lymphocytes, particularly in the gut. Therefore, the blockade of IL-7R prevents pathogenic T cells from entering gut tissue to cause inflammatory bowel disease (IBD).

Memory T cells circulate for years after an initial infection and prompt faster future responses to their specific antigens. According to Dr Poirier, the production of memory T cells against autoantigens is responsible for the chronicity of autoimmune conditions such as IBD, because each time we have an expansion of memory T cells which recognise autoantigens, we have a relapse of the disease.

Dr Poirier also added that OSE-127 has a further action; IL-7 signalling effects transcription, promoting the proliferation and survival of T cells. By blocking this action, OSE-127 prevents the long-term survival of immune cells such as memory T cells.

Dr Poirier explained that the main challenges in the field of autoimmune therapy research are obtaining and using models that accurately reflect the human condition and immune system.

He revealed: one of most challenging aspects of targeting the immune system is the translation from technical research which is based on in vitro assays on human cells and in vivo in mice to then a therapeutic in a human patient.

According to Dr Poirier, they are now involved in a human translational immunology programme to overcome the inaccuracies of animal models. Within this programme they are moving away from the use of animal models and instead are developing ex vivo tissue sample assays from patients. As part of the project, they have access to samples, such as skin from psoriasis patients or colon tissue from IBD patients, on which they can directly test drug candidates on the pathogenic tissue that contains both the pathogenic and regulatory immune cells. Using this we can directly demonstrate or identify if the drugs work exactly as we want.

Dr Poirier also revealed that these therapies are still proof-of-concept, from which they intend to learn and optimise their system. Due to their therapeutics targeting the immune system, rather than a localised specific tissue, the products are transferable between different autoimmune conditions. As a result, he suggested that the time spent modifying and developing these pharmaceuticals to be as efficacious and targeted as possible, will make future developments less costly because they can continue to modify and extend the indications. A further area of discovery Dr Poirier believes will be important in the future is working on actively resolving inflammation in autoimmune conditions.

Dr Poirier presents a novel approach for the treatment of autoimmune conditions, moving away from past techniques of broad immunosuppression and towards selectively activating and repressing different subtypes of immune cells. Moving forward, Dr Poirier suggests there will be further modification and development of their mAb fragments in order to target other immune cells related to different conditions.

He also highlighted that progression in R&D models, such as ex vivo patient tissue samples, should also contribute to future success and drug discovery.

Related topicsAntibodies, Biologics, Biopharmaceuticals, Disease research, Drug Development, Drug Discovery Processes, Drug Targets, Monoclonal Antibody, Research & Development, t-cells, Therapeutics

Originally posted here:
Rebalancing the immune system to treat autoimmune disease - Drug Target Review

Mens Journal aims to feature only the best products and services. We update when possible, but deals expire and prices can change. If you buy something via one of our links, we may earn a commission.Questions? Reach us at shop@mensjournal.com.

Its getting pretty real out there folks. The world has decided to put our immune systems to the test with the coronavirus. If we dont take the proper precautions, we can get sick and no one wants that. You can wash your hands all day long and keep away from people. But if your immune system isnt up to snuff, it can be all for naught. So head on over to Amazon to pick up the Genius Mushroom Lions Mane Immunity Booster to make sure it is.

When you pick up the Genius Mushroom Lions Mane Immunity Booster, you will be on the right road to having a healthier body. Even without the coronavirus shaking up the world, you dont want to get sick. Even the common cold can make day to day living difficult. These pills get your immune system in top shape because they are made with three of the best mushrooms in the world.

Not all mushrooms are the same. There are plenty of varieties out there. And the three that comprise the Genius Mushroom Lions Mane Immunity Booster work really well at improving your body. It is made with cordyceps, lions mane, and reishi mushrooms. Each one bringing a specific benefit to your life that will make your days a lot easier to get through.

The reishi mushroom is the mushroom that makes the Genius Mushroom Lions Mane Immunity Booster great for this current corona situation. Ingesting it gives your immune system a boost. But you wont just get those benefits from reishi. You will also help clean out your liver to help aid in the immune process. And it has been found to improve your mood.

Thats not all you will get with the Genius Mushroom Lions Mane Immunity Booster. With cordyceps, your energy will increase. No need to ingest caffeine. You will have all the juice you need to tackle the day. And with Lions Mane, you will get a big blast of cognitive clarity. Your memory will increase, as will your focus. Together that means you will be on the top of your game at work.

If you have any worries about the coronavirus, you should pick up the Genius Mushroom Lions Mane Immunity Booster. It will help you fight back against this annoying disease. Youll also get a boost during the day to make work so much easier to deal with. And for those of you that like to work out, all of this adds up to make it easier to lose weight and get into shape. So pick up a bottle now. No need to wait.

Get It: Pick up the Genius Mushroom Lions Mane Immunity Booster ($22; was $24) at Amazon

Check out the great products and gear we recommend to Mens Journal readers

For access to exclusive gear videos, celebrity interviews, and more, subscribe on YouTube!

Read the rest here:
Get Your Immune System In Top Shape With This Immunity Booster - Men's Journal

These cells play a key protective role in immunity to infection however, if unregulated, they can also cause tissue damage in autoimmune disorders.

The research, published in theJournal of Experimental Medicine, should help us design more effective vaccines to prevent infections such as MRSA and may also assist help us develop of new therapies for autoimmune diseases, such as multiple sclerosis or rheumatoid arthritis.

The immune system functions to control infection, utilising various immune cells, such as T cells to respond to and control invading microbes. However, if these immune cells are not highly regulated, they can attack and damage body tissues, leading to the development of autoimmune diseases.

Molecules called T cell receptors (TCRs) allow T cells to recognise components of infectious agents with exquisite specificity. The TCRs enable T cells to respond to and eventually eliminate the infectious agent.

Professor Kingston Mills, Professor of Experimental Immunology, School of Biochemistry and Immunology in the Trinity Biomedical Sciences Institute, Dublin explained that: Until now scientists thought that there were two discrete populations of T cells, expressing either or TCRs. The s are the most common T cells in the body.

They play a key role in remembering prior infection or immunisation and thereby help protect us against re-infection and mediate vaccine-induced protective immunity. The s are more prevalent at mucosal surfaces, such as the lung or gut, and provide an immediate first line of defence against pathogens that invade through these routes.

We have discovered a new cell type that expresses both and TCRs. This rare population of chimeric or hybrid - T cells has properties of both and T cells. Importantly, they are normally highly activated and poised to act as first responders to control bacterial infection.

However, given this high level of activation, they are effectively Jekyll and Hyde cells because in certain contexts they can also precipitate autoimmune responses.

Using a model of Staphylococcus aureus infection, Mills and his team found that these cells are rapidly mobilised during infection and play a key role in quickly eliminating the microbes from the body.

By introducing these hybrid - T cells, it may represent a novel approach in the design of more effective vaccines against Staph aureus and other infectious diseases, while advancing our ability to control their response may yield additional therapeutic options.

Mills added: In a model of autoimmune disease, we found that the hybrid T cells can also trigger the inflammatory cascade that mediates tissue damage in autoimmunity. Therefore, approaches for inhibiting these highly activated immune cells in susceptible individuals may open up new approaches for the treatment of autoimmune diseases such as psoriasis and multiple sclerosis.

Originally posted here:
The 'Jekyll and Hyde' of immune cells - Health Europa

Its the time of year when we start reaching for the Berocca tablets in an attempt to keep those cold and flu viruses at bay.

But with the recent spread of coronavirus to the UK, its never been more important to keep your inner security guard in tip-top condition.

Its no surprise that eating well, getting a good nights sleep and washing your hands regularly can help support your bodys ability to fight off infections, but are there other ways to boost your bodys defence mechanism?

Heres how the immune system works, and how to keep it in balance...

So what is it?

The immune system is a network of cells, organs, proteins and antibodies that work to protect you against bacteria, viruses and parasites. It doesnt only work when we feel ill.

Every day we inhale one hundred million viruses, according to the Medical Research Council, and the immune systems job is to keep us safe. There are two main parts: the innate response and the acquired response.

The innate response works out what is friend and foe, then tries to flush out the invader its this that can make us feel feverish or snotty. The acquired response remembers specific invaders and sends the right cells to kill them off.

How do you stop germs spreading?

The NHS says the best defence against germs is to follow basic hygiene washing hands with hot soapy water, or using hand sanitiser.

Use a tissue or your sleeve to catch a cough or sneeze, and avoid touching your eyes, nose and mouth if your hands are not clean.

Does wearing a face mask help?

Since the outbreak of coronavirus, sales of face masks have risen 800%, and its likely youve seen people wearing them in busy locations, like at train stations or in airports.

But there is no conclusive evidence to suggest they can stop virus particles from entering the mouth and throat. They may stop you self-contaminating by putting your hands in your mouth or nose.

What about supplements?

Many over-the-counter products claim to boost your immune system, but there is little evidence to show that they do. If you have a poor diet, it may help to take a daily multi-vitamin, but if you are healthy and eat well getting lots of fibre, fruit, veg and healthy fats your immune system should have everything it needs to run optimally.

Age matters

Unfortunately, the immune system declines by about 2-3% a year from our 20s, which is why older people are more susceptible to infections, says Janet Lord, professor of immune cell biology at the University of Birmingham. Death rates from diseases like pneumonia and bronchitis are three times higher among elderly people.

1. Spice things up Season your food with garlic, onions, ginger, turmeric and cayenne pepper. These have antioxidant, detoxification and antimicrobial properties.

2. Drink green tea Its rich in antioxidants called Polyphenols, which are efficient infection fighters.

3. Get enough sleep A good nights sleep (were talking 7-9 hours) can bolster the T cells, which fight infection in the body. One study also showed that just one night of 4 hours sleep depleted the bodys natural killer cells by 70%.

4. Reduce stress The brain and the immune system are in constant communication when we are stressed, the brain produces more cortisol and prepares the body for emergency situations. But while it is doing that, it depresses our immune system. Try relaxation exercises like yoga or meditation. Positive thinking can also go a long way.

5. Keep warm It turns out its true what your mother said cold viruses are more infectious at temperatures lower than 37C, which is the average core body temperature. So wrap up warm when you go outside.

6. Fluids, fluids, fluids Staying hydrated helps your body naturally eliminate toxins and other bacteria that might cause illness. Aim for at least eight glasses of water a day.

7. Essential oils Lemon has powerful antibacterial properties and has been shown to stimulate the production of white blood cells, which fight off infections. Diffuse six drops of lemon oil in a diffuser (like the Tisserand Aroma Spa Diffuser, 39.95) to help give your immune system a boost.

Follow this link:
7 ways to improve your immune system that are better than coronavirus face masks - Mirror Online

Researchers have studied how the human body responds to viral infection when already infected by fungi, offering insights into the immune system.

New research has found that the bodys immune response to fungal infections changes when a patient is also infected by a virus.The study, carried out by researchers at the University of Birmingham, the Pirbright Institute and University College London, all UK, sheds fresh light on the immune systems ability to deal with co-infection.

Although clinicians understand how the immune system responds to fungal and viral infections, much less is known about what happens when both occur together.

Typically, white blood cells will attack pathogens through phagocytosis where a pathogen is engulfed by the white blood cell. In fungal infections, however, this process sometimes reverses ejecting the fungus back out of the white blood cell via a process called vomocytosis. The researchers were able to show that this process of expulsion is rapidly accelerated when the white blood cells detect a virus.

The team used advanced microscopy techniques to study live white blood cells exposed to two different types of virus, HIV and measles, alongside the fungal pathogen, Cryptococcus neoformans. This opportunistic pathogen is particularly deadly among HIV+ patients.

Instead of becoming simply less able to deal with the fungus, the researchers found that the white blood cells began expelling the fungal cells much more rapidly.

Lead author, Professor Robin May, Director of the Institute of Microbiology and Infection at the University of Birmingham, explained: We found the macrophages ejected their prey the fungal cells much more quickly when the virus was present. This was very unexpected, but could be an attempt to free up those white blood cells to deal with the new viral invaders.

The team used advanced microscopy techniques to study live white blood cells

As the vomocytosis occurred with both viruses, the researchers concluded that the effect was likely to be a general response to viral co-infection.

Professor May added: This is the first time that scientists have studied our immune systems response to fungal infection in the much more realistic setting of a secondary (viral) infection. We dont yet know whether this mechanism makes the white blood cells more or less effective in fighting off either infection. Although expelling the fungal cell will free up the macrophage to attack the virus, it also sets free the fungal cell to continue its spread through the body.

Dr Dalan Bailey, head of the Viral Glycoproteins group at Pirbright, commented: This is another interesting example of transkingdom interactions between microbes, this time fungi and viruses. We are only beginning to understand the complexity of microbe interactions within the host and this collaboration sheds new light on this exciting new area of research.

Investigating these processes in animal models will be the next step for the team, with a longer term goal of harnessing the mechanisms used to trigger the expulsion of fungi and use them to help clear these pathogens from the body.

The study was published in PLOS Pathogens.

View original post here:
Study reveals how immune system handles fungal and viral infections - Drug Target Review

BURLINGAME, Calif., March 4, 2020 /PRNewswire/ --Inflammatix, a pioneering molecular diagnostics company delivering precision medicine at the point of care, announced findings from a new study published today in Nature Communicationsthat demonstrate its ability to identify patients with bacterial versus viral infections using a data-driven approach that measures the immune system response. The molecular classifier used in the study forms the basis of Inflammatix's HostDx rapid tests, which the company is developing to overcome traditional challenges of diagnosing acute infections and sepsis.

"When seeing a sick patient with a suspected infection in the emergency room, most physicians are forced to basically make an educated guess about whether the patient has a bacterial or viral infection, and then treat accordingly. Unfortunately, despite best efforts, this guessing game can have terrible outcomes for patients and for our health system," said Tim Sweeney, M.D., Ph.D., cofounder and chief executive officer of Inflammatix.

"For 20 years, researchers have been looking for a way to use transcriptomics the study of the body's gene expression to classify patients with acute infections. To date, others' attempts to apply machine learning to this problem have not held up when applied to diverse patient populations. Our new study is the first time that a locked, multi-gene signature has been validated in a blinded, independent clinical cohort. It represents a major technical breakthrough in translating our tests to the clinic."

For the new publication, Inflammatix and Stanford University scientists applied advanced machine learning to develop a 29-gene classifier ("BVN-1") that can identify bacterial, viral or no infections across 1,069 blood samples from 18 prior studies of patients diagnosed with acute infections. The patients represented a wide range of geographic regions, clinical care setting and disease contexts.

The researchers then tested the locked classifier i.e., without modification or retraining on an independent cohort of 109 patients from Stanford University's intensive care unit who underwent evaluation for acute infection and sepsis. They found that the test was highly accurate in diagnosing infections, especially among patients tested within 36 hours of hospital admission a critical time for determining treatment. Among this subset, the test demonstrated an AUROC of 0.92 (95% CI; 0.83-0.99) for identifying patients with bacterial infections and 0.91 (95% CI; 0.82-0.98) for viral infections.

The molecular classifier also demonstrated higher accuracy than standard biomarkers -- procalcitonin (PCT) and C-reactive protein (CRP) that have been associated with acute infections and sepsis. Among the subset of patients with PCT and CRP results in the Stanford ICU cohort, the Inflammatix test had an AUROC of 0.87 (95% CI; 0.8-0.94) for bacterial infections, compared to 0.83 (95% CI; 0.75-0.92) for PCT and 0.70 (95% CI; 0.6-.081) for CRP. Neither PCT nor CRP could positively identify viral infections.

"To wit, 100 percent of the patients in this cohort were on antibiotics, but many did not have an underlying bacterial infection. Improved diagnostics would benefit patients and have a major impact on the healthcare system," said Dr. Sweeney.

"Furthermore, our machine learning team has demonstrated the power of our computational platform in a highly heterogeneous and difficult field. We look forward to bringing the same computational tools to bear across multiple other infectious and inflammatory diseases."

Antibiotic resistance and sepsis lead to more than 700,0001 and 5 million2 respective deaths worldwide each year. Inflammatix's HostDx Sepsis and HostDx Fever tests use proprietary machine learning algorithms that incorporate the expression of multiple immune genes (host response) to identify the presence of bacterial or viral infections and to determine if a patient has or is likely to develop sepsis. Inflammatix's simple-to-use, sample-to-answer HostDx system is designed to produce results at or near the point of care in 30 minutes or less. The company plans to advance its HostDx tests through commercial launch in Europe and submission to the United States Food and Drug Administration in 2021.

In January 2020, Inflammatix announced it had received $32 million in Series C financing. Prior to that, in November 2019, the company announced a cost-sharing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, to further develop its HostDx tests. The agreement is worth up to $72 million based on achieving certain milestones.*

CitationMayhew, MB et al. A generalizable 29-mRNA neural-network classifier for acute bacterial and viral infections. Nature Communications, 2020.https://doi.org/10.1038/s41467-020-14975-w

About InflammatixInflammatix is a molecular diagnostics company that is reimagining diagnostics by "reading" the patient's immune system to deliver rapid results that improve patient care and reduce major public health burdens. The company's initial focus is on acute infection and sepsis, where its HostDx tests combine proprietary biomarkers and advanced machine learning to help physicians quickly get the right treatments to the right patients. Each test will be developed to run on the company's sample-to-answer isothermal instrument platform in under 30 minutes, enabling the power of precision medicine at the point of care. The Burlingame, Calif.-based company funders include Khosla Ventures, Northpond Ventures, Think.Health Ventures, Grey Sky Venture Partners and the Stanford-StartX Fund. For more information, please visit http://www.inflammatix.com and follow the company on Twitter (@Inflammatix_Inc).

*This project has been funded in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract Nos. 75A50119C00034 and 75A50119C00044.

Media Contact: Tracy Morris650-380-4413tracymorrispr@gmail.com

1Interagency Coordination Group on Antimicrobial Resistance. No Time to Wait: Securing the Future from Drug-Resistant Infections; Report to the United Nations. April 2019.2Rudd KE, et al. Global, regional, and national sepsis incidence and mortality, 19902017: analysis for the Global Burden of Disease Study. Lancet 2020; 395:200-211.

View original content to download multimedia:http://www.prnewswire.com/news-releases/new-inflammatix-study-in-nature-communications-outlines-breakthrough-in-diagnosing-acute-infections-by-reading-the-immune-system-301016311.html

SOURCE Inflammatix

Here is the original post:
New Inflammatix Study in Nature Communications Outlines Breakthrough in Diagnosing Acute Infections by Reading the Immune System - BioSpace

As cases ofcoronavirusspread around the world, doctors are learning more about what it does to the human body. Most cases are mild, but the illness officially known as COVID-19 can become severe if a person's immune system cannot repair damage to the lungs caused by the virus, CBS News medical contributor Dr. Tara Narula said. The disease has infected almost 89,000 people worldwide and killed more than 3,000 people. In the United States, the death toll rose to six on Monday.

"The issue with COVID-19 is that this virus can affect the lower tract of your airways," Narula, a cardiologist at Northwell Health, said Monday on "CBS This Morning." The virus can damage the cells that line the respiratory tract in the lungs, she explained. When that happens, "your immune system launches a response to try to clean up and repair."

But for some people, the immune system response "is so overwhelming, it's not in check," Narula said. If that's the case, the lungs can be flooded with fluid and cellular debris.

"Essentially the lungs start to drown, and that's a situation that can become a severe pneumonia. The pneumonia can then progress to what we call sepsis, where you can have a drop of blood pressure and multi-organ failure, and that's how it really causes death," she said.

In China, where the virus originated, 80% of cases have been mild, Narula said.

"Only about 14% were severe and even less were critical," she said.

Some research has estimated the death rate at about 2%, Narula said, but added that it's probably lower because there are likely more mild cases than what have been detected.

"In the grand scheme of things, for most people if they get it, it will end up being a mild disorder," she said.

Narula said the virus is transmitted through person-to-person contact by droplets.

"So if I cough or sneeze, those droplets can travel up to six feet and enter your mouth, or your nose or your lungs," she said. "Another way is if I cough or sneeze and it lands on a surface or an object and then you touch that same object or surface and touch your face."

Symptoms include fever, cough and shortness of breath. People could also have a headache, diarrhea, muscle aches, sore throat, runny nose and congestion, Narula said.

An infected person can pass on the virus to others even if they are not showing any symptoms.

Visit link:
What the coronavirus does to the body and how it can become severe - CBS News

India confirms a total of 28 coronavirus cases

The coronavirus outbreak has affected a total of 70 countries around the world. India reportedtwo fresh cases of coronavirus on Monday, one in Delhi and the other in Telangana. With the biggest jump in numbers, Indiareportsa total of 28 cases as of today. A group of 15 Italian tourists who traveled Rajasthan last month tested positive. Union health minister Harsh Vardhan told the media that the positive case reported in Delhi interacted with his family of six members in Agra. All six members are infected from the virus.

COVID-19 can spread easily from an infected person. It can cause symptoms like cough, shortness of breath, fatigue, sore throat and some may experience difficulty in breathing. Currently, there is no vaccine to prevent the spread of coronavirus. it is important to avoid any panic situation insteadfollow the right prevention methods to fight the spread of coronavirus.

A strong immune system can help you fight the infection naturally. Lifestyle coach Luke Coutinho sharessome amazingtips to boost one's immunity to stay safe during thisoutbreak.

"A virus can impact someone with low immunity. So if you have a low immune system, viruses, bacteria, infections are more likely to affect you as compared to those with strong immunity," Luke explains. In the video, he stresses on the importance of a strong immune system and explains that if you maintain a strong immune system, you can possibly prevent a viral infection. Even if you get it, a strong system can help you fight against it effectively.

Avoid public gatherings to prevent coronavirus spreadPhoto Credit: iStock

Several foods can help you boost immunity but Luke highlights that foods alone will not boost your immune system. It has to be combined with sleep, exercise, stress management and many other factors.

Also read:Delhi Reports First Case And One More In Telangana; WHO Guidelines On How Use Masks To Protect Against Coronavirus

1. Ginger has strong immunity-boosting properties. Include it in your foods or prepare ginger tea.

2. Spinach, not in the raw form can also help you boost immunity. Steam or boil it lightly as it to prepare an immunity-boosting recipe.

3. Yogurt is great for your gut health. A healthy gut promotes strong immune system.

4. Almonds are loaded with nutrients. A handful of almonds or 8-10 almonds can be consumed daily.

5. Turmeric is one of the best options you must add to your diet for better immunity. But it should be combined with black pepper and good fat like coconut oil or pure ghee. Take a half tablespoon of turmeric, one tablespoon of ghee or coconut oil and a small amount of pepper. It will boost the absorption of turmeric.

6. Green tea is a healthy beverage. You can drink up to 2-3 cups of fresh green daily.

7. Add more fruits to your diet. Fruits like papaya, berries and kiwi are some great immunity boosters.

8. Add more protein to your diet. A virus affects the tissues and can destroy cells and protein helps in repairing tissues. Make sure that you add a small amount of protein to every meal.

9. Sunflower seeds and pumpkin seeds are also great immunity boosters.

10. Garlic is also loaded with immunity-boosting properties. Consume raw garlic or boil some garlic and ginger in hot water to prepare a tea.

11. A healthy soup with a combination of cabbage, broccoli, cauliflower, spinach, tomato, onion, garlic, ginger, pumpkin and turmeric.

Add more immunity boosting foods to your dietPhoto Credit: iStock

Also read:Coronavirus Outbreak In India: Samples Taken From 6 People In Noida Test Negative

Other tips to boost immunity-

Luke suggests you must combine other healthy practices with a diet loaded with immunity boosters. Some of these include-

1. Proper sleep

2. Regular exercise- at least 30 minutes of exercise

3. Wash your hands more often or use a sanitiser

4. Try deep breathing or pranayam to supply more oxygen to the body

5. Beat stress with yoga, meditation, exercise or other activities you like

Also read:Flu Shots Can Prevent Coronavirus - This And Other Myths Busted

Disclaimer: This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.

Read the rest here:
India Confirms 28 Coronavirus Cases; Do Not Panic But Boost Your Immunity With These Amazing Expert Tips To Fight It - NDTV News

Miskawaan Health Group Medical Director Dr Johannes Wessolly outlines key steps to improving the immune system

With the novel coronavirus (2019-nCoV) epidemic bringing parts of the world to a panic-stricken standstill, now is the best time to think about the state of ones overall health and wellbeing and just how susceptible you might be to an infection.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200304005875/en/

Miskawaan Health Group Medical Director Dr Johannes Wessolly. (Photo: Business Wire)

Global average life expectancy increased 5.5 years between the years 2000 and 2016, according to the World Health Organization (WHO). While our life expectancy is rising, all too often, our quality of life is not enhanced in an equal measure. For over 30 years, Miskawaan Health Groups Medical Director, Dr Johannes Wessolly, has used a functional medicine approach to tailoring treatments for his patients in a natural and effective manner.

At the forefront of functional medicine, Miskawaan uses highly accredited doctors, scientists, and oncologists as well as technology solutions such as artificial intelligence and machine learning to innovate and create cutting-edge, highly personalised treatments for patients. Founded by Dr Wessolly & David Boehm, Miskawaan fuses its offering of the best of German technology with the art of Thai hospitality to ensure peace of mind, excellent health and longevity for its clients.

Below, Dr Wessolly highlights a few important steps toward improving the immune system, safeguarding the body against disease, and advancing optimal health.

In life and in health, defense is the best offense.

None of us need to be told that proper nutrition and restful sleep are two of the basic keys to maintaining mental and physical wellbeing, and yet, for one reason or another, were not doing either of those enough. To effectively shield the body against the novel coronavirus and other viruses for that matter means actively seeking ways to lower ones vulnerability to infection. Keep your immune system as strong as it can be by ensuring sufficient intake of vitamins, in particular vitamins C and D and zinc, which together work as boosters for the system. If you find yourself in a congested area, wear a mask and make sure you disinfect your hands as often as possible.

Despite the prevalence of the most advanced technologies for curing a spectrum of diseases, the saying prevention is better than cure still holds water. Be intentional in your investment in long-term solutions to the protection of your health.

Treat the cause, not the symptom.

Instead of waiting until you feel something might be amiss, recognise that time is of the essence, and that what you do today could greatly affect the trajectory of your health in the future. Where traditional medicine is structured to manage symptoms, functional medicine strives to address the causes. In functional medicine, a doctor will ask why a person is sick and then try to understand if there are underlying dysfunctions that are causing a condition instead of simply masking its symptoms with a prescription.

Recognising the complexity of the human body as one biological system rather than a collection of organs, Miskawaans doctors begin with a comprehensive one-on-one session that lasts a minimum of 60 minutes. During this in-depth consultation, our doctors look for interactions among genetic, environmental, hormonal and lifestyle factors that can influence chronic inflammation and long-term health. Illness may manifest differently and progress at varying speeds depending on the body, and that is precisely due to these markers. We strive to identify the why before approaching the how.

Story continues

In addition to personalised nutritional programmes and post-disease recovery support, Miskawaan offers infusions and injections, from 100% natural customised proprietary IV infusions to therapies for cancer, diabetes, mitochondria and more, making treatments available to patients at every stage of their health journey.

Its all personal.

Every person is genetically and biochemically unique, so why do we believe that a traditional, one-size-fits-all approach of prescribing the same medications will work? The approach should be patient-centric rather than the traditional disease-centric.

Functional medicine is a philosophy of optimal health, where the complexity of the human body is examined through alternate interpretations of diagnostic data and health treatments are customised for each patient.

Holistic diagnostics, punctuated with a personal touch that references warm Thai hospitality, is the hallmark of every Miskawaan clinic. At Miskawaan, which carries out more extensive testing through its own biotechnology lab and collaborative health technology ecosystem supported by access to the top labs across the globe, diagnostics include testing for food intolerance, heavy metals and minerals, blood and pathology, cardiovascular and peripheral-vascular, and metabolic profiling.

In functional medicine, a personalised health treatment plan targets the specific manifestations of disease in each individual. Our goal is to use natural therapy to maximise the inherent efficiency of the immune system. We then work with you to embark on a health roadmap with the objective of improving health and vitality.

Visit http://www.miskawaanhealth.com for more information.

Please download high-resolution images through this link: http://ftp.catchonco.com/Miskawaan.zip.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200304005875/en/

Contacts

For media enquiries or interview opportunities, please contact CatchOn, a Finn Partners Company: Manica Tiglao Direct Line: (852) 2807 0899 | Email: manica.tiglao@finnpartners.com

Originally posted here:
Why Functional Medicine is the Future of Healthcare - Yahoo Finance

WASHINGTON The mother of an American imprisoned in Iran said Wednesday she fears her son is at risk of contracting the coronavirus given the scale of the outbreak in the country and reports that the illness has spread to a major prison where he was held temporarily.

Michael White, a U.S. Navy veteran, had just finished treatment for cancer when he was detained in Iran in July 2018, according to his mother, Joanne White.

"For months, Iranian authorities have refused to provide Michael, a cancer patient with a compromised immune system, with basic medical care and his health has rapidly declined," Joanne White said in a statement issued Wednesday.

"I believe his life is imminently at risk and the situation is made even more urgent by the fact it's been a month since we last had verifiable proof Michael is alive," White said.

Let our news meet your inbox. The news and stories that matters, delivered weekday mornings.

Michael White was recently transferred from a prison in Mashad to Evin prison in Tehran, she said, where he stayed 11 days until he was returned to Mashad. The lawyer for another American held in Iran, Siamak Namazi, said Monday the coronavirus was detected at Evin and one inmate who tested positive was removed.

Iranian authorities insist the virus has not been found in Evin prison. But on Tuesday, a judiciary spokesman said at a press conference that 54,000 prisoners have been temporarily released to prevent the spread of coronavirus in Iranian prisons.

"I am also concerned by credible reports of an outbreak at Evin prison because, at the end of January, Michael was suddenly transferred from Mashhad to Evin where he spent eleven days in a cramped intake cell before being returned to Mashhad without explanation," Joanne White said.

Given his fragile health, there was a serious danger that Michael White could die behind bars, she said.

"Time is running out for the Iranian regime to release Michael alive and avoid the consequences that would certainly follow should he die in their custody,' she said.

Joanne White, who said her son voted for President Donald Trump, demanded the White House take action to secure her son's release.

"It is also long past time for the administration my son so proudly voted for to DO SOMETHING to bring him home," she said in the statement.

A State Department spokesperson told NBC News that officials are "working with the Swiss on a daily basis to ensure the health, safety, and release of U.S. citizens currently imprisoned in Iran."

Iran has denied any mistreatment of foreign prisoners or that it withholds adequate medical care. Iran's U.N. mission was not immediately available for comment.

Iranian authorities have struggled to contain the spread of coronavirus. The illness has killed 92 people in Iran and there are 2,922 confirmed cases of the virus, according to the country's health ministry spokesman.

Dan De Luceis a reporter for the NBC News Investigative Unit.

View post:
Mother of American held in Iran fears her son is at risk of infection from coronavirus - NBC News